Reduced DDB2 Expression Is Associated with Temozolomide Resistance in Glioblastoma Cells
Glioblastoma (GBM) remains one of the most lethal primary brain tumours, and resistance to temozolomide (TMZ), the standard chemotherapeutic agent for GBM, represents a major obstacle to effective treatment. Although O6-methylguanine-DNA methyltransferase (MGMT) is a well-established determinant of TMZ response, MGMT s...